

## Sensorion Announces Its Attendance at the 41<sup>st</sup> Annual J.P. Morgan Healthcare Meeting in San Francisco

MONTPELLIER, France--([BUSINESS WIRE](#))-- Regulatory News:

**Sensorion (FR0012596468 – ALSEN)** a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce that its management team, including Chief Executive Officer Nawal Ouzren, will be attending the 41<sup>st</sup> Annual J.P. Morgan Healthcare Meeting, between 09-12 January 2023, in San Francisco, USA.

Sensorion will meet with potential partners and investors to address ongoing and future strategic developments within the company, including developments on SENS-401, its small molecule, currently being developed in two Phase 2 clinical studies. Sensorion is also pursuing two gene therapy programs, OTOF-GT, for the treatment of otoferlin gene-mediated hearing loss, and GJB2-GT, targeting hearing loss due to mutations in the GJB2 gene, the most common form of deafness.

If you wish to book a meeting with Sensorion's management team, please contact us by email at [ir@sensorion-pharma.com](mailto:ir@sensorion-pharma.com).

### About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.

Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies.

Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

Sensorion pursues its broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in *GJB2* gene to potentially address important hearing loss segments in adults and children (GJB2-GT). The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

[www.sensorion.com](http://www.sensorion.com)

Label: **SENSORION**  
ISIN: **FR0012596468**  
Mnemonic: **ALSEN**

### Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The

communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

## Contacts

### **Investor Relations**

Noemie Djokovic

Investor Relations and Communications

+33 6 76 67 98 31

[ir.contact@sensorion-pharma.com](mailto:ir.contact@sensorion-pharma.com)

### **International Media Relations**

Consilium1 Strategic Communications

Matthew Cole/Jessica Hodgson

+44 7593 572720

+44 7561 424788

[Sensorion@consilium-comms.com](mailto:Sensorion@consilium-comms.com)

Source: Sensorion